Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference
25 March 2020 - 11:00PM
Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or “Company”), a
leader in the commercialization and development of prescription
ophthalmology treatments for the management of retinal diseases,
today announces that nine posters on ILUVIEN® (fluocinolone
acetonide intravitreal implant) 0.19 mg for intravitreal injection
will be available online during and after the 11th Annual Congress
on Controversies in Ophthalmology (COPHy) conference beginning
March 27, 2020, a yearly congress held virtually this year due to
precautions around the coronavirus.
Highlighted posters include:
- “Benefit of Early ILUVIEN Treatment – Chronicity of Diabetic
Macular Edema as Predictor of Visual and Anatomical Outcomes” to be
presented by J. Heitor Marques, Department of Ophthalmology, Centro
Hospitalar Universitário do Porto, Portugal
http://cophy.comtecmed.com/groupa/29a.pdf
- “Fluocinolone Acetonide Intravitreal Implant Outcomes on the
Prevention of Relapse in Recurrent Birdshot Retinochoroidopathy:
3-Year Outcomes” to be presented by M. Cordeiro and M. Guedes
Department of Ophthalmology, Centro Hospitalar de Lisboa Ocidental,
Portugal http://cophy.comtecmed.com/groupb/31b.pdf
About the 11th Annual Congress on Controversies in
Ophthalmology: Europe Virtual Conference The program will
be devoted to evidence-based debates examining and analyzing the
most relevant and controversial issues raised during the course of
2019 and 2020 within the field of Retina. A three-hour online
meeting will take place on March 27th and March 28th and include
live interactive question and answer sessions and two COPHy
90-minute debates. Abstracts will be hosted on the website.
About Alimera Sciences, Inc. Alimera Sciences
is a pharmaceutical company that specializes in the
commercialization and development of prescription ophthalmic
pharmaceuticals for the management of retinal diseases. Alimera is
presently focused on diseases affecting the back of the eye, or
retina, because these diseases are not well treated with current
therapies and will affect millions of people in our aging
populations. For more information, please visit
www.alimerasciences.com.
About
ILUVIEN®
The Company’s primary product is ILUVIEN (fluocinolone acetonide
intravitreal implant) 0.19 mg sustained release intravitreal
implant, injected into the back of the eye. With its CONTINUOUS
MICRODOSING™ technology, ILUVIEN is designed to release
sub-microgram levels of fluocinolone acetonide, a corticosteroid,
for 36 months, to reduce the recurrence of disease, enabling
patients to maintain vision longer with fewer injections. ILUVIEN
is approved in the U.S., Canada, Kuwait, Lebanon and the U.A.E to
treat diabetic macular edema (DME) in patients who have been
previously treated with a course of corticosteroids and did not
have a clinically significant rise in intraocular pressure. In 17
European countries, ILUVIEN is indicated for the treatment of
vision impairment associated with chronic DME considered
insufficiently responsive to available therapies. In March 2019,
ILUVIEN received approval in the 17 countries under the Mutual
Recognition Procedure for prevention of relapse in recurrent
non-infectious uveitis affecting the posterior segment of the eye.
The 17 European countries include the U.K., Germany, France, Italy,
Spain, Portugal, Ireland, Austria, Belgium, Denmark, Norway,
Finland, Sweden, Poland, Czech Republic, the Netherlands, and
Luxembourg. The non-infectious posterior uveitis indication for
ILUVIEN was launched in Germany and the U.K. in 3Q 2019. ILUVIEN is
not approved for treatment of uveitis in the United
States.For press inquiries:Jules Abrahamfor
Alimera Sciences917-885-7378julesa@coreir.comFor investor
inquiries:Scott Gordonfor Alimera
Sciencesscottg@coreir.com
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2024 to May 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From May 2023 to May 2024